BeiGene / BeOne Medicines Patent-Cliff Exposure & CMS Drug Spending Portfolio
BeiGene / BeOne Medicines (San Mateo, CA): 3 reconciled FDA prescription therapies, $1.77B 2024 CMS Part D & Medicaid spend, and $39,720 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | San Mateo, CA |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2039-01-01 |
| 2024 CMS Total Public Spend | $1.77B |
| 2024 Medicare Part D Spend | $1.72B |
| 2024 Medicaid Spend | $47.1M |
| California HCAI SB 17 Filings | Specialty launch notice ($39,720 intro WAC) |